Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 12th Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Provisions)

In August 2026, 4,740 of the 12th Stock Acquisition Rights were exercised, and 474,000 new shares were issued. As of month-end, 95,260 rights remained unexercised, equivalent to 9,526,000 shares.

Worth reading
60In focus
Scored from 3 of 5 sections
Direction
Deterioration
Direction inferred from the company’s description.
Scale
474000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status of the 12th stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)

Who receives how much

Shares issued during the month: 474,000 shares (474,000 new shares and 0 treasury shares transferred)

EVO FUND (issued on 7 August 2026)

The lower thin line represents the existing number of shares to which these shares will be added.

発行済株式総数

Exercise ratio subject to exercise restrictions: 3.31% (474,000 shares / 14,305,000 shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise price during the month: ¥103–¥127 per share. The floor under the adjustment clause is Not disclosed
Number of Stock Acquisition Rights
Total issued: 100,000 rights; unexercised as of 7 August 2026: 100,000 rights; unexercised as of month-end: 95,260 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
7 August 2026: Issuance of the 12th Stock Acquisition Rights, with EVO FUND as the allottee, with an exercise price adjustment clause. Amount: Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status of the 12th stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
Number of shares to be issued or disposed ofShares issued during the month: 474,000 shares (474,000 new shares and 0 treasury shares transferred)
Intended allotteeEVO FUND (issued on 7 August 2026)
Dilution RateExercise ratio subject to exercise restrictions: 3.31% (474,000 shares / 14,305,000 shares)
Total number of issued shares14,305,000 shares (as of 7 August 2026, including 198 treasury shares) → Not disclosed
Exercise priceExercise price during the month: ¥103–¥127 per share. The floor under the adjustment clause is Not disclosed
Number of Stock Acquisition RightsTotal issued: 100,000 rights; unexercised as of 7 August 2026: 100,000 rights; unexercised as of month-end: 95,260 rights
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing7 August 2026: Issuance of the 12th Stock Acquisition Rights, with EVO FUND as the allottee, with an exercise price adjustment clause. Amount: Not disclosed
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This is a report on the monthly exercise status, and the company has provided no explanation of the reasons for the exercises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 12th Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Provisions) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori